obinutuzumab plus bendamustine in rituximab-refractory indolent non-Hodgkin lymphoma

2 Views
administrator
administrator
07/09/23

Chicago ASCO Annual Meeting 2015:: Press Briefing Targeted Therapy: Saturday, May 30 - Laurie Helen Sehn, Neil Sun Chua, Jiri Mayer, et al. GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
More info: http://oncoletter.ch

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next